Last reviewed · How we verify
Urea cream based
Urea cream acts as a keratolytic and humectant agent that softens and hydrates the stratum corneum, facilitating removal of hyperkeratotic tissue and improving skin barrier function.
Urea cream acts as a keratolytic and humectant agent that softens and hydrates the stratum corneum, facilitating removal of hyperkeratotic tissue and improving skin barrier function. Used for Hyperkeratotic skin conditions, Xerosis and dry skin disorders, Ichthyosis and related keratinization disorders.
At a glance
| Generic name | Urea cream based |
|---|---|
| Also known as | Urea cream |
| Sponsor | University of Brasilia |
| Drug class | Keratolytic agent / Humectant |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Urea penetrates the outer layer of skin and disrupts hydrogen bonds between keratin filaments, thereby softening and loosening dead skin cells. Simultaneously, it functions as a humectant by drawing moisture into the epidermis, which enhances hydration and promotes skin healing. This dual action makes it effective for conditions characterized by abnormal keratinization and xerosis.
Approved indications
- Hyperkeratotic skin conditions
- Xerosis and dry skin disorders
- Ichthyosis and related keratinization disorders
Common side effects
- Local irritation or burning sensation
- Transient erythema
- Pruritus
Key clinical trials
- An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PHASE3)
- Efficacy and Safety of Moisturising Cream With or Without Vitamin E and Urea Cream in Palmar-plantar Erythrodysesthesia (NA)
- Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy (NA)
- Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR (NA)
- Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC (PHASE1)
- Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases (PHASE1)
- Effectiveness of an N-acetylcysteine and Urea-based Cream in Prevention of Capecitabine-induced HAND-foot Syndrome in Breast Cancer Patients (NA)
- Topical Cosmetic Products for Hand and Foot Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urea cream based CI brief — competitive landscape report
- Urea cream based updates RSS · CI watch RSS
- University of Brasilia portfolio CI